Alimera Sciences, Inc.
Alimera Sciences develops and commercializes prescription ophthalmic retinal pharmaceuticals. The company offers ILUVIEN for diabetic macular edema and recurrent non-infectious uveitis. It also provides YUTIQ for treating non-infectious uveitis. Products are sold through direct sales and distributors to physician offices, clinics, pharmacies, and hospitals. Alimera has collaborations with EyePoint Pharmaceuticals and Ocumension (Hong Kong) Limited. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (7.81) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (8.44%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 50.4 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 7.8 |